Page last updated: 2024-11-04

trimethobenzamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

trimethobenzamide: major descriptor (64-84); on-line search BENZAMIDES (64-84); Index Medicus search TRIMETHOBENZAMIDE (64-84); RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

trimethobenzamide : The amide obtained by formal condensation of 3,4,5-trihydroxybenzoic acid with 4-[2-(N,N-dimethylamino)ethoxy]benzylamine. It is used to prevent nausea and vomitting in humans. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5577
CHEMBL ID1201256
CHEBI ID27796
SCHEMBL ID28858
MeSH IDM0262805

Synonyms (96)

Synonym
n-{4-[2-(dimethylamino)ethoxy]benzyl}-3,4,5-trimethoxybenzamide
trimetobenzamida
CHEBI:27796 ,
trimethobenzamidum
BRD-K34415467-003-05-6
KBIO1_000425
DIVK1C_000425
n-[(4-{[2-(dimethylamino)ethyl]oxy}phenyl)methyl]-3,4,5-tris(methyloxy)benzamide
SPECTRUM_000117
benzamide, n-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4,5-trimethoxy-
cas-554-92-7
NCGC00016509-01
PRESTWICK3_000080
PRESTWICK2_000080
SPECTRUM5_000969
IDI1_000425
BSPBIO_002934
AB00053561
C07178
138-56-7
trimethobenzamide
n-[[4-(2-dimethylaminoethoxy)phenyl]methyl]-3,4,5-trimethoxybenzamide
DB00662
BSPBIO_000299
trimetobenzamida [inn-spanish]
4-(2-dimethylaminoethoxy)-n-(3,4,5-trimethoxybenzoyl)benzylamine
benzamide, n-((4-(2-(dimethylamino)ethoxy)phenyl)methyl)-3,4,5-trimethoxy-
benzamide, n-(p-(2-(dimethylamino)ethoxy)benzyl)-3,4,5-trimethoxy-
trimethobenzamide [inn]
hsdb 3198
n-((2-dimethylaminoethoxy)benzyl)-3,4,5-trimethoxybenzamide
einecs 205-332-1
trimethobenzamidum [inn-latin]
KBIOSS_000557
KBIO2_005693
KBIO3_002154
KBIOGR_000861
KBIO2_000557
KBIO2_003125
SPECTRUM4_000371
NINDS_000425
SPBIO_002220
SPBIO_000827
PRESTWICK0_000080
PRESTWICK1_000080
SPECTRUM3_001377
SPECTRUM2_000844
BPBIO1_000329
NCGC00016509-02
NCGC00016509-03
trimethobenzamide (inn)
D08643
ametik damla (tn)
AKOS007167113
benzacot
unii-w2x096qy97
stemetic
tribenzagan
w2x096qy97 ,
ametik damla
CHEMBL1201256
trimethobenzamide [hsdb]
trimethobenzamide [who-dd]
trimethobenzamide [vandf]
trimethobenzamide [mi]
gtpl7614
SCHEMBL28858
n-(4-[2-(dimethylamino)ethoxy]benzyl)-3,4,5-trimethoxybenzamide #
n-[p-[2-(dimethylamino)ethoxy]benzyl]-3,4,5-trimethoxybenzamide
FEZBIKUBAYAZIU-UHFFFAOYSA-N
n-(4-(2-(dimethylamino)ethoxy)benzyl)-3,4,5-trimethoxybenzamide
emedur
HMS3604F21
AB00053561_08
DTXSID8023711 ,
n-({4-[2-(dimethylamino)ethoxy]phenyl}methyl)-3,4,5-trimethoxybenzamide
Z667611948
SBI-0051546.P002
boc-(s)-3-amino-3-(4-cyano-phenyl)-propionicacid
Q7842199
BRD-K34415467-003-08-0
D94499
n-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4,5-trimethoxybenzamide
NCGC00016509-08
EN300-119183
4-(2-dimethylaminoethoxy)-n-(3,4,5-trimethoxybenzoyl)benzylamine; n- {4-[2-(dimethylamino)ethoxy]benzyl}-3,4,5-trimethoxybenzamide
A886218
AS-76970
CS-0012340
HY-12751
dtxcid403711
n-((4-(2-dimethylaminoethoxy)phenyl)methyl)-3,4,5-trimethoxybenzamide
r06aa10
trimethobenzamidum (inn-latin)
trimetobenzamide
trimetobenzamida (inn-spanish)

Research Excerpts

Effects

ExcerptReferenceRelevance
"Trimethobenzamide (TMB) has a pregnancy category C labeling. "( Growth failure, tardive dyskinesia, megacolon development, and hepatic damage in neonatal rats following exposure to trimethobenzamide in utero.
Gokcimen, A; Goksu Erol, AY; Ozdemir, O, 2011
)
2.02
"Trimethobenzamide (TMB) has a pregnancy category C labeling. "( Growth failure, tardive dyskinesia, megacolon development, and hepatic damage in neonatal rats following exposure to trimethobenzamide in utero.
Gokcimen, A; Goksu Erol, AY; Ozdemir, O, 2011
)
2.02

Toxicity

ExcerptReferenceRelevance
"In this study, we aimed to investigate and compare the direct toxic and teratogenic effects of dimenhydrinate, metoclopramide and trimethobenzamide HCl, antiemetic drugs on embryonic growth and development in cultured rat embryos."( Investigation of developmental toxicity and teratogenicity of antiemetics on rat embryos cultured in vitro.
Acar, H; Fazliogullari, Z; Karabulut, AK; Unver Dogan, N; Uysal, II, 2013
)
0.59

Dosage Studied

An ion-pair column chromatographic method was developed for the determination of trimethobenzamide hydrochloride in capsules and injection dosage forms.

ExcerptRelevanceReference
"An ion-pair column chromatographic method was developed for the determination of trimethobenzamide hydrochloride in capsules and injection dosage forms."( Ion-pair column chromatographic determination of trimethobenzamide hydrochloride in capsule and injection dosage forms: collaborative study.
Naviasky, H,
)
0.61
"An ion-pair column chromatographic/UV spectrophotometric method for assaying trimethobenzamide hydrochloride in capsules and injections is presented, as well as a method for the detection of 3,4,5- trimethoxybenzoic acid in trimethobenzamide hydrochloride bulk drug and dosage forms."( Quantitative analysis of trimethobenzamide hydrochloride by ion-pair column chromatography and semiquantitative analysis of 3,4,5-trimethoxybenzoic acid by thin-layer chromatography.
Naviasky, H, 1984
)
0.8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antiemeticA drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centres (the vomiting centre and the chemoreceptive trigger zone) or affect the peripheral receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
benzamides
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 2C19 precursorHomo sapiens (human)Potency6.30960.00255.840031.6228AID899
lamin isoform A-delta10Homo sapiens (human)Potency0.05620.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (69)

TimeframeStudies, This Drug (%)All Drugs %
pre-199043 (62.32)18.7374
1990's10 (14.49)18.2507
2000's7 (10.14)29.6817
2010's8 (11.59)24.3611
2020's1 (1.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 55.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index55.52 (24.57)
Research Supply Index4.42 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index89.53 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (55.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (7.89%)5.53%
Reviews1 (1.32%)6.00%
Case Studies2 (2.63%)4.05%
Observational0 (0.00%)0.25%
Other67 (88.16%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease [NCT02373072]Phase 118 participants (Actual)Interventional2015-03-31Completed
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, And Pharmacokinetics Of Pf 06649751 Co-administered With Trimethobenzamide Hydrochloride In Healthy Volunteers [NCT02262767]Phase 19 participants (Actual)Interventional2014-11-30Completed
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action [NCT01770145]Phase 4127 participants (Actual)Interventional2012-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01770145 (1) [back to overview]"Change From Baseline in Average Daily Time to on (TTO) by Subject Diary."

"Change From Baseline in Average Daily Time to on (TTO) by Subject Diary."

"Patients will record daily time to on or TTO following their regularly scheduled first L-Dopa dose in the baseline period for 7 consecutive days. Following initiation on Apokyn therapy, patients will inject Apokyn at their regularly scheduled L-Dopa time (L-Dopa dosing will be delayed by 40 minutes following Apokyn injection) and record time to on or TTO from the injection. Time to on for both periods will be recorded in a standardized subject diary. Daily TTO for the baseline period will be averaged for each subject and compared to the daily TTO for the same subject during the treatment period to assess APOKYN's effect on TTO." (NCT01770145)
Timeframe: L-Dopa Baseline Days 1-7 and APOKYN Treatment Days 1-7

Interventionminutes (Mean)
BaselineTreatment PeriodChange from Baseline
APOKYN60.8623.7237.14

[back to top]